Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies
Retrieved on:
Thursday, June 3, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical trials, Medical specialties, Circulatory system, Cardiovascular system, GABAA receptor positive allosteric modulators, Atherosclerosis, Cholesterol, Niacin, Omega-3 fatty acid, High-density lipoprotein, Cardiovascular disease, Epeleuton, the TRIAGE trial, Afimmune, EPELEUTON, THE TRIAGE TRIAL, AFIMMUNE
Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.
Key Points:
- Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.
- Any new therapeutic that can decrease or prevent atherosclerosis is expected to have a significant impact on cardiovascular outcomes, including mortality.
- In addition to these large reductions in atherosclerosis progression, epeleuton statistically significantly decreased triglycerides, cholesterol and inflammatory markers, including serum interleukin-1 beta (IL-1).
- The strong effects of epeleuton on atherosclerosis, shown for the first time in these preclinical studies, further emphasises the exciting therapeutic potential of this novel omega 3 drug.